natgillin/translations-raw huggingface dataset:
88 In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
84 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
89 Handling of the pen
85 Ravnanje z injekcijskim peresnikom
90 4.8 Undesirable effects
4. 8 Neželeni učinki
91 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
87 Tako kot pri zdravljenju z vsakim insulinom se lahko na mestu injiciranja pojavi lipodistrofija, ki upočasni lokalno absorpcijo insulina.
92 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
In healthy subjects, the serum half-life of insulin is approximately 4 to 6 minutes.
88 Pri zdravih osebah je razpolovni čas insulina v serumu približno 4 do 6 minut.
The pen in-use or carried as a spare may be stored for a maximum of 4 weeks not above 25°C away from direct heat or direct light.
Rok uporabnosti po prvi uporabi injekcijskega peresnika Injekcijski peresnik, ki ga uporabljate ali ga imate pri sebi za rezervo lahko shranjujete največ 4 tedne pri temperaturi do 25 °C zaščiteno pred neposredno toploto ali svetlobo.
93 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
Each cartridge contains 3 balls (stainless steel).
89 3 ml suspenzija v vložku (iz brezbarvnega stekla tipa 1), z batom iz brombutilne gume (tipa 1) ter s prirobljeno aluminijsko zaporko z zamaškom iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1).
Injection needles are not included in the pack.
V vsakem vložku so 3 kroglice (iz nerjavnega jekla).
Insulin Human Winthrop Basal must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulina Insulin Human Winthrop Basal se ne sme uporabiti, če tega ni mogoče doseči, tj. suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno vložka.
Insulin Human Winthrop Basal must not be mixed with any other insulin or with insulin analogues.
Insulin Human Winthrop Basal se ne sme mešati z nobenim drugim insulinom ali insulinskimi analogi.
94 Handling of the pen The Instructions for Use included in the Package Leaflet must be read carefully before using OptiSet.
90 Ravnanje z injekcijskim peresnikom Pred uporabo OptiSeta natančno preberite navodila za ravnanje z OptiSetom v navodilu za uporabo.
The insulin should be mixed by turning OptiSet slowly up and down at least 10 times.
91 Insulin je treba premešati tako, da OptiSet vsaj 10- krat počasi obrnete navzgor in navzdol.
The appearance of the insulin should be checked: the insulin suspension must have an evenly milky white appearance.
Prav tako je treba preveriti izgled insulina: suspenzija insulina mora biti enakomerno mlečno bela.
95 Step 2.
Korak 2.
The injection button allows checking the actual loaded dose.
92 Gumb za injiciranje omogoča preverjanje dejansko napolnjenega odmerka.
96 The patient should be informed on the injection technique by his health care professional.
Pristojni zdravstveni delavec mora bolnika poučiti o načinu injiciranja.
This helps prevent contamination and/ or infection as well as entry of air into the insulin reservoir and leakage of insulin, which can cause inaccurate dosing.
To pomaga preprečiti onesnaženje in/ ali okužbo, pa tudi vstopanje zraka v rezervoar z insulinom in iztekanje insulina, kar lahko povzroči nenatančno odmerjanje.
Each ml contains 100 IU insulin human (equivalent to 3.5 mg).
En mililiter Insulin Human Winthropvsebuje 100 i. e. humanega insulina (kar ustreza 3, 5 mg).
98 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insulin Human Winthrop Basal in cartridges for OptiClik has been developed for use with OptiClik only.
Insulin Human Winthrop Basal v vložkih za injekcijski peresnik OptiClik je pripravljen samo za uporabo v injekcijskih peresnikih OptiClik.
99 In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
95 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
100 Intercurrent illness
Sočasne bolezni
A number of substances affect glucose metabolism and may require dose adjustment of human insulin.
96 Na presnovo glukoze vplivajo številna zdravila oz. snovi in potrebna utegne biti prilagoditev odmerka humanega insulina.
101 4.8 Undesirable effects
4. 8 Neželeni učinki
Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.
97 Hude hipoglikemije lahko povzročijo nevrološke okvare, zlasti če se ponavljajo.
102 Skin and subcutaneous tissue disorders
Bolezni kože in podkožja
Common: injection site reactions Uncommon: injection site urticaria Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
98 Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
103 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
Protamine sulphate, metacresol, phenol, zinc chloride, sodium dihydrogen phosphate dihydrate, glycerol, sodium hydroxide, hydrochloric acid (for pH adjustment), water for injections.
Protaminijev sulfat, metakrezol, fenol, cinkov klorid, atrijev dihidrogenfosfat dihidrat, glicerol, natrijev hidroksid, klorovodikova kislina (za uravnavanje pH), voda za injekcije.
104 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
3 ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
3 ml suspenzija v vložku (iz brezbarvnega stekla tipa 1) z batom (iz brombutilne gume (tipa 1)) in prirobljeno zaporko (iz aluminjija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
6.6 Special precautions for disposal and other handling
100 6. 6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom
Insulin pen The cartridges for OptiClik are to be used in conjunction OptiClik only and as recommended in the information provided by the device manufacturer.
Insulinski injekcijski peresnik Vložki za injekcijski peresnik OptiClik se uporabljajo samo skupaj z injekcijskim peresnikom OptiClik in po navodilih izdelovalca injekcijskega peresnika.
Cartridges Before insertion into the pen, Insulin Human Winthrop Basal must be kept at room temperature for 1 to 2 hours and then resuspended to check the contents.
Vložki Pred vstavitvijo v injekcijski peresnik mora biti Insulin Human Winthrop Basal 1 do 2 uri na sobni temperaturi, potem pa ga je treba za preverjanje vsebine ponovno suspendirati.
Insulin Human Winthrop Basal cartridges for OptiClik are not designed to allow any other insulin to be mixed in the cartridge for OptiClik.
Vložki Insulin Human Winthrop Basal za injekcijski peresnik OptiClik niso zasnovani tako, da bi dovoljevali mešanje kakšnega drugega insulina v vložku za injekcijski peresnik OptiClik.
105 Any unused product or waste material should be disposed of in accordance with local requirements.
Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi.
Each pen contains 3 ml of suspension for injection, equivalent to 300 IU insulin.
Vsak injekcijski peresnik vsebuje 3 ml raztopine za injiciranje, kar ustreza 300 i. e. insulina.
SoloStar.
Suspenzija za injiciranje v napolnjenem injekcijskem peresniku SoloStar.
Alternatively, it may emerge gradually over a period of several weeks.
103 Po drugi strani pa se lahko pojavi postopoma med obdobjem več tednov.
107 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
108 In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
104 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
109 Handling of the pen
105 Ravnanje z injekcijskim peresnikom
110 4.8 Undesirable effects
4. 8 Neželeni učinki
111 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
107 Tako kot pri zdravljenju z vsakim insulinom se lahko na mestu injiciranja pojavi lipodistrofija, ki upočasni lokalno absorpcijo insulina.
112 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
In healthy subjects, the serum half-life of insulin is approximately 4 to 6 minutes.
108 Pri zdravih osebah je razpolovni čas insulina v serumu približno 4 do 6 minut.
113 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
3 ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
109 3 ml suspenzija v vložku (iz brezbarvnega stekla tipa 1), z batom (iz brombutilne gume (tipa 1)) ter s prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
114 Handling of the pen
pokrovček peresnika
115 Step 2.
111 Korak 2.
EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX
112 EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX
117 1.
113 1.
Insulin Human Winthrop Comb 15 100 IU/ ml suspension for injection in a vial
Insulin Human Winthrop Comb 15 100 i. e. / ml suspenzija za injiciranje v viali
Insulin Human Winthrop Comb 15 is a biphasic isophane insulin suspension consisting of 15% dissolved insulin and 85% crystalline protamine insulin.
Insulin Human Winthrop Comb 15 je dvofazna suspenzija insulina izofana, sestavljena iz 15% raztopljenega insulina in 85% kristalnega protamin- insulina.
118 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
114 Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insulin Human Winthrop Comb 15 contains 100 IU of insulin per ml suspension.
En mililiter suspenzije Insulin Human Winthrop Comb 15 vsebuje 100 i. e. insulina.
119 In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.
Pri bolnikih z okvaro ledvic se lahko potreba po insulinu zaradi zmanjšane presnove insulina zmanjša.
In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
115 Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
120 Intercurrent illness
Sočasne bolezni
4.5 Interaction with other medicinal products and other forms of interaction
116 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Insulin Human Winthrop Comb 15 can be used during breastfeeding.
Zdravilo Insulin Human Winthrop Comb 15 je med dojenjem dovočljeno uporabljati.
121 4.8 Undesirable effects
4. 8 Neželeni učinki
Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.
117 Hude hipoglikemije lahko povzročijo nevrološke okvare, zlasti če se ponavljajo.
122 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
Tako kot pri zdravljenju z vsakim insulinom se lahko na mestu injiciranja pojavi lipodistrofija, ki upočasni lokalno absorpcijo insulina.
Common: injection site reactions Uncommon: injection site urticaria Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
118 Občasni: urtikarija na mestu injiciranja Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
Insulins and analogues, intermediate-acting combined with fast-acting, ATC Code:
Insulini s srednje dolgim delovanjem, s takojšnjim učinkom in analogi, oznaka ATC:
Insulin Human Winthrop Comb 15 (a biphasic isophane insulin suspension with 15% dissolved insulin) is an insulin with gradual onset and long duration of action.
Insulin Human Winthrop Comb 15 (dvofazna suspenzija insulina izofana s 15% raztopljenega insulina) je insulin s postopnim začetkom in dolgim trajanjem delovanja.
123 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
The acute toxicity was studied following subcutaneous administration in rats.
119 Akutno toksičnost so proučili po subkutani uporabi pri podganah.
Store in a refrigerator (2°C - 8°C).
Neodprte viale Shranjujte v hladilniku (2 °C - in 8 °C).
124 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
Before withdrawing insulin from the vial for the first time, remove the plastic protective cap.
120 Pred prvim izvlekom insulina iz viale odstranite plastično zaščitno zaporko.
Insulin Human Winthrop Comb 15 must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the vial.
Insulina Insulin Human Winthrop Comb 15 se ne sme uporabiti, če tega ni mogoče doseči – če suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno viale.
As with all insulin preparations, Insulin Human Winthrop Comb 15 must not be mixed with solutions containing reducing agents such as thioles and sulphites.
Tako kot velja za vse pripravke insulinov, tudi zdravila Insulin Human Winthrop Comb 15 ne smete mešati z raztopinami, ki vsebujejo reducente, npr. tiole ali sulfite.
It must also be remembered that
Zavedati se je treba, da:
- insulin protamine crystals dissolve in an acid pH range,
- se kristali insulin protamina raztapljajo v kislem pH območju,
- the soluble insulin part precipitates out at a pH of approximately 4.5 to 6.5.
- topni del insulina precipitira v območju pH približno od 4, 5 do 6, 5.
Insulin Human Winthrop Comb 15 may be mixed with all Sanofi-Aventis human insulins, but NOT with those designed specifically for use in insulin pumps.
Insulin Human Winthrop Comb 15 se sme mešati z vsemi humanimi insulini, ki jih izdeluje Sanofi - Aventis, NE pa s tistimi, ki so posebej pripravljeni za uporabo v insulinskih črpalkah.
Insulin Human Winthrop Comb 15 must also NOT be mixed with insulins of animal origin or with insulin analogues.
Zdravila Insulin Human Winthrop Comb 15 prav tako NE smete mešati z insulini živalskega izvora ali insulinskimi analogi.
126 1.
121 1.
Insulin Human Winthrop Comb 15 40 IU/ ml suspension for injection in a vial
Insulin Human Winthrop Comb 15 40 i. e. / ml suspenzija za injiciranje v viali
127 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
122 Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insulin Human Winthrop Comb 15 contains 40 IU of insulin per ml suspension.
En mililiter suspenzije Insulin Human Winthrop Comb 15 vsebuje 40 i. e. insulina.
The injection syringes must not contain any other medicinal product or residue (e. g. traces of heparin).
Injekcijske rizge ne smejo vsebovati nobenega drugega zdravila ali ostankov (npr. sledov heparina).
128 In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.
Pri bolnikih z okvaro ledvic se lahko potreba po insulinu zaradi zmanjšane presnove insulina zmanjša.
In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
123 Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
129 Intercurrent illness
Sočasne bolezni
4.5 Interaction with other medicinal products and other forms of interaction
124 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Insulin Human Winthrop Comb 15 can be used during breastfeeding.
Zdravilo Insulin Human Winthrop Comb 15 je med dojenjem dovoljeno uporabljati.
130 4.8 Undesirable effects
4. 8 Neželeni učinki
Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.
125 Hude hipoglikemije lahko povzročijo nevrološke okvare, zlasti če se ponavljajo.
131 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
Tako kot pri zdravljenju z vsakim insulinom se lahko na mestu injiciranja pojavi lipodistrofija, ki upočasni lokalno absorpcijo insulina.
Common: injection site reactions Uncommon: injection site urticaria Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
126 Občasni: urtikarija na mestu injiciranja Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
132 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
The acute toxicity was studied following subcutaneous administration in rats.
127 Akutno toksičnost so proučili po subkutani uporabi pri podganah.
Concerning mixing or incompatibility with other insulins see section 6.6.
Glede mešanja in inkompatibilnosti z drugimi insulini glejte poglavje 4. 2.
133 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
6.6 Special precautions for disposal and other handling
128 6. 6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom
135 1.
129 1.
Insulin Human Winthrop Comb 15 100 IU/ ml suspension for injection in a cartridge
Insulin Human Winthrop Comb 15 100 i. e. / ml suspenzija za injiciranje v vložku
Each ml contains 100 IU insulin human (equivalent to 3.5 mg).
En mililiter vsebuje 100 i. e. humanega insulina.
136 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
130 Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insulin Human Winthrop Comb 15 in cartridges has been developed for use in the OptiPen series.
Insulin Human Winthrop Comb 15 v vložkih je pripravljen za uporabo v injekcijskih peresnikih OptiPen.
137 In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
131 Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
138 Intercurrent illness
Sočasne bolezni
4.5 Interaction with other medicinal products and other forms of interaction
132 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens (e. g. in oral contraceptives), phenothiazine derivatives, somatropin, sympathomimetic agents (e. g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, protease inhibitors and atypical antipsychotic medicinal products (e. g. olanzapine and clozapine).
Med zdravili oz. snovmi, ki lahko oslabijo hipoglikemično delovanje, so kortikosteroidi, danazol, diazoksid, diuretiki, glukagon, izoniazid, estrogeni in progestageni (npr. v kontracepcijskih tabletah), derivati fenotiazina, somatropin, simpatikomimetiki (npr. adrenalin, salbutamol, terbutalin), ščitnični hormoni, zaviralci proteaz in netipična antipsihotična zdravila (npr. olanzapin in klozapin).
139 4.8 Undesirable effects
4. 8 Neželeni učinki
Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.
133 Hude hipoglikemije lahko povzročijo nevrološke okvare, zlasti če se ponavljajo.
140 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
Tako kot pri zdravljenju z vsakim insulinom se lahko na mestu injiciranja pojavi lipodistrofija, ki upočasni lokalno absorpcijo insulina.
Common: injection site reactions Uncommon: injection site urticaria Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
134 Občasni: urtikarija na mestu injiciranja Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
141 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
The acute toxicity was studied following subcutaneous administration in rats.
135 Akutno toksičnost so proučili po subkutani uporabi pri podganah.
The cartridge in-use (in the insulin pen) or carried as a spare may be stored for a maximum of 4 weeks not above 25°C away from direct heat or direct light.
Rok uporabnosti po prvi uporabi vložka Vložek, ki ga uporabljate (v injekcijskem peresiku) ali ga imate pri sebi za rezervo, lahko shranjujete največ 4 tedne pri temperaturi do 25 °C zaščiteno pred neposredno toploto ali svetlobo.
142 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
Packs of 3, 4, 5, 6, 9 or 10 cartridges are available.
136 Na voljo so pakiranja s 3, 4, 5, 6, 9 ali 10 vložki.
Cartridges Before insertion into the pen, Insulin Human Winthrop Comb 15 must be kept at room temperature for 1 to 2 hours and then resuspended to check the contents.
Pred vstavitvijo v injekcijski peresnik mora biti Insulin Human Winthrop Comb 15 1 do 2 uri na sobni temperaturi, potem pa ga je treba za preverjanje vsebine ponovno suspendirati.
Insulin Human Winthrop Comb 15 must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulina Insulin Human Winthrop Comb 15 se ne sme uporabiti, če tega ni mogoče doseči – če suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno vložka.
143 Any unused product or waste material should be disposed of in accordance with local requirements.
137 Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi.
144 1.
138 1.